SGLT2 inhibition, acylcarnitines and heart failure: a Mendelian randomization study
MR analysis indicated SGLT2 inhibition showed associations with acylcarnitines, which are also associated with HF risk. Our findings highlighted the potential involvement of acylcarnitines in the mechanisms between SGLT2 inhibitors and HF.
Authors
- Hong Chen Guo
- Ling Yang (ORCID: https://orcid.org/0000-0001-5750-6588)
- Dianjianyi Sun (ORCID: https://orcid.org/0000-0003-3651-6693)
- Canqing Yu (ORCID: https://orcid.org/0000-0002-0019-0014)
- Dan Schmidt (ORCID: https://orcid.org/0000-0003-0704-8165)
- Shuyao Song (ORCID: https://orcid.org/0000-0002-5025-6341)
- Iona Y. Millwood (ORCID: https://orcid.org/0000-0002-0807-0682)
- Yuanjie Pang
- Robin G. Walters (ORCID: https://orcid.org/0000-0002-9179-0321)
- Jun Lv (ORCID: https://orcid.org/0000-0001-7916-3870)
- Zhiyu Wu
- Liming Li (ORCID: https://orcid.org/0000-0002-5798-2362)
- Zhengming Chen (ORCID: https://orcid.org/0000-0001-6423-105X)
- Pei Pei (ORCID: https://orcid.org/0000-0003-3411-6792)
- Xiaoming Yang (ORCID: https://orcid.org/0000-0003-2482-8673)
- Yiping Chen
- Junshi Chen
Institutions
- Peking University (CN)
- University of Oxford (GB)
- China National Center for Food Safety Risk Assessment (CN)
- Liuyang City Maternal and Child Health Hospital (CN)
- Anyang Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Open Heart
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/openhrt-2024-003078
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Cancer Research UK
- British Heart Foundation
- University of Oxford
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
- Medical Research Council
- Beijing Nova Program